

# Cost effectiveness analysis of improved blood pressure with type 2 diabetes: UKPDS 40

BMJ: British Medical Journal

317, 720-726

DOI: [10.1136/bmj.317.7160.720](https://doi.org/10.1136/bmj.317.7160.720)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Diabetes: a time for excitement--and concern. BMJ: British Medical Journal, 1998, 317, 691-692.	2.3	19
2	Combined high blood pressure and glucose in type 2 diabetes: double jeopardy. BMJ: British Medical Journal, 1998, 317, 693-694.	2.3	72
3	United Kingdom Prospective Diabetes Study: the end of the beginning?. Medical Journal of Australia, 1998, 169, 511-512.	1.7	0
4	Management of retinopathy in type 2 diabetes. Eye, 1999, 13, 131-132.	2.1	1
5	Other Articles Noted. Evidence-based Nursing, 1999, 2, 105-112.	0.2	0
6	The UK Prospective Diabetes Study (UKPDS): clinical and therapeutic implications for type 2 diabetes. British Journal of Clinical Pharmacology, 1999, 48, 643-648.	2.4	436
7	The natural history of diabetes-related complications: the UKPDS experience. Diabetes, Obesity and Metabolism, 1999, 1, 7-13.	4.4	29
8	A systematic review of foot ulcer in patients with Type 2 diabetes mellitus. I: prevention. Diabetic Medicine, 1999, 16, 801-812.	2.3	129
9	A Bayesian approach to stochastic cost-effectiveness analysis. Health Economics (United Kingdom), 1999, 8, 257-261.	1.7	205
10	Intensive antihypertensive treatment to the new lower blood pressure targets. Current Hypertension Reports, 1999, 1, 313-319.	3.5	2
11	United Kingdom Prospective Diabetes Study (UKPDS): what now or so what?. Diabetes/Metabolism Research and Reviews, 1999, 15, 65-71.	4.0	35
12	Erectile dysfunction in patients with diabetes. British Journal of Hospital Medicine, 1999, 60, 638-644.	0.2	35
13	Hypertension in patients with diabetes. Postgraduate Medicine, 2000, 107, 29-38.	2.0	38
14	Managing blood pressure in type 2 diabetes mellitus. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2000, 17, 49-53.	0.2	3
15	Angiotensin converting enzyme (ACE) activity levels in insulin-independent diabetes mellitus and effect of ACE levels on diabetic patients with nephropathy. , 2000, 18, 23-28.		25
16	Making a case for inclusion of new oral anti-diabetic agents in drug formularies. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2000, 17, 141-146.	0.2	0
17	Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Economics (United Kingdom), 2000, 9, 623-630.	1.7	253
18	The cost of diabetes: time for a different approach?. Diabetic Medicine, 2000, 17, 820-822.	2.3	10

#	ARTICLE	IF	CITATIONS
19	Direct medical costs for patients with type 2 diabetes in Sweden. <i>Journal of Internal Medicine</i> , 2000, 248, 387-396.	6.0	123
20	Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. <i>BMJ: British Medical Journal</i> , 2000, 321, 412-419.	2.3	1,737
21	Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. <i>European Journal of Heart Failure</i> , 2000, 2, 447-454.	7.1	30
22	Systematic review and economic evaluation of <i>Helicobacter pylori</i> eradication treatment for non-ulcer dyspepsia. <i>BMJ: British Medical Journal</i> , 2000, 321, 659-664.	2.3	296
23	Study of the quality of care at a diabetic clinic in Sri Lanka. <i>Perspectives in Public Health</i> , 2000, 120, 164-169.	0.4	6
24	Complications of diabetes: renal disease and promotion of self-management. <i>Quality in Health Care: QHC</i> , 2000, 9, 257-263.	1.2	5
25	Treatment of hypertension in patients ≥65 years of age: experience with amlodipine. <i>Clinical Therapeutics</i> , 2000, 22, 1473-1482.	2.5	6
26	Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study. <i>Diabetes Research and Clinical Practice</i> , 2000, 48, 201-210.	2.8	91
27	Diabetes – a common, growing, serious, costly, and potentially preventable public health problem. <i>Diabetes Research and Clinical Practice</i> , 2000, 50, S77-S84.	2.8	227
28	Life-expectancy projection by modelling and computer simulation (UKPDS 46). <i>Diabetes Research and Clinical Practice</i> , 2000, 50, S5-S13.	2.8	22
29	Preserving renal function in adults with hypertension and diabetes: A consensus approach. <i>American Journal of Kidney Diseases</i> , 2000, 36, 646-661.	1.9	1,314
30	Cost effectiveness of initial endoscopy for dyspepsia in patients over age 50 years: a randomised controlled trial in primary care. <i>Lancet</i> , 2000, 356, 1965-1969.	13.7	120
31	Cost Estimates for Chronic Diseases. <i>Disease Management and Health Outcomes</i> , 2000, 8, 29-41.	0.4	8
32	Pharmacoeconomic Considerations in the Management of Hypertension. <i>Drugs</i> , 2000, 59, 13-20.	10.9	42
33	β-Blockers in the Management of Hypertension in Patients with Type 2 Diabetes Mellitus. <i>Drugs</i> , 2001, 61, 429-435.	10.9	7
34	Optimizing the Delivery of Effective Diabetes Care. <i>Disease Management and Health Outcomes</i> , 2001, 9, 683-690.	0.4	0
35	The impact of diabetes on economic costs in dialysis patients: experiences in Taiwan. <i>Diabetes Research and Clinical Practice</i> , 2001, 54, 47-54.	2.8	32
36	An initial assessment of the feasibility and effectiveness of implementing diabetes shared care system in Taiwan – some experiences from I-Lan County. <i>Diabetes Research and Clinical Practice</i> , 2001, 54, 67-73.	2.8	34

#	ARTICLE	IF	CITATIONS
37	The methodologic partnership of effectiveness reviews and cost-effectiveness analysis. American Journal of Preventive Medicine, 2001, 20, 10-12.	3.0	97
38	Clinical impact and health economic consequences of posttransplant type 2 diabetes mellitus. Transplantation Proceedings, 2001, 33, S32-S39.	0.6	7
39	Cost-Effectiveness Analysis of Inhaled Zanamivir in the Treatment of Influenza A and B in High-Risk Patients. Pharmacoeconomics, 2001, 19, 293-301.	3.3	32
40	What is the Optimal Blood Pressure in Patients with Diabetes Mellitus?. American Journal of Cardiovascular Drugs, 2001, 1, 173-177.	2.2	3
41	Treatment of Hypertension in Patients with Diabetes: Lessons from Recent Trials. Cardiology in Review, 2001, 9, 36-44.	1.4	9
42	Cardiovascular disease in diabetes: prevention and intervention. Current Opinion in Endocrinology, Diabetes and Obesity, 2001, 8, 101-110.	0.6	3
43	Disease Management and Pharmacoeconomics as Tools for Mass Prevention of Hypertensive Complications. Heart Disease (Hagerstown, Md ), 2001, 3, 152-156.	1.3	4
45	Cardiovascular Risk Management in Type 2 Diabetes: From Clinical Trials to Clinical Practice. , 2001, 11, 474-490.		7
46	An economic evaluation of atenolol vs. captopril in patients with Type 2 diabetes (UKPDS 54). Diabetic Medicine, 2001, 18, 438-444.	2.3	18
47	Attaining UKPDS management targets in type 2 diabetes: failures and difficulties. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2001, 18, 307-310.	0.2	8
48	A framework for cost-effectiveness analysis from clinical trial data. Health Economics (United Kingdom), 2001, 10, 779-787.	1.7	82
49	Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Economics (United Kingdom), 2001, 10, 779-787.	1.7	885
50	Microalbuminuria in type 2 diabetic hypertensive patients in ASCOT. Journal of Human Hypertension, 2001, 15, S79-S80.	2.2	0
51	Analysis, Sample Size, and Power for Estimating Incremental Net Health Benefit from Clinical Trial Data. Contemporary Clinical Trials, 2001, 22, 228-237.	1.9	48
52	On the probability of cost-effectiveness using data from randomized clinical trials. BMC Medical Research Methodology, 2001, 1, 8.	3.1	15
53	Economic evaluation of strategies for managing crying and sleeping problems. Archives of Disease in Childhood, 2001, 84, 15-19.	1.9	105
54	Perceived Difficulty of Diabetes Treatment in Primary Care: Does it Differ by Patient Ethnicity?. The Diabetes Educator, 2001, 27, 678-684.	2.5	10
55	Review: UKPDS odyssey 2001. British Journal of Diabetes and Vascular Disease, 2001, 1, 14-21.	0.6	2

#	ARTICLE	IF	CITATIONS
56	Cost effectiveness of an outpatient multidisciplinary pulmonary rehabilitation programme. <i>Thorax</i> , 2001, 56, 779-784.	5.6	261
57	A UK trial-based cost-utility analysis of transmyocardial laser revascularization compared to continued medical therapy for treatment of refractory angina pectoris. <i>European Journal of Cardio-thoracic Surgery</i> , 2001, 20, 312-318.	1.4	21
58	Treatment of Hypertension in the Elderly. <i>The American Journal of Geriatric Cardiology</i> , 2002, 11, 11-22.	0.6	14
59	Bayesian methods for design and analysis of cost-effectiveness trials in the evaluation of health care technologies. <i>Statistical Methods in Medical Research</i> , 2002, 11, 469-490.	1.5	55
60	Clinical Trial Evidence for Cardiovascular Risk Reduction in Type 2 Diabetes. <i>Journal of Cardiovascular Nursing</i> , 2002, 16, 24-43.	1.1	6
61	Implementing intensive control of blood glucose concentration and blood pressure in type 2 diabetes in England: cost analysis (UKPDS 63). <i>BMJ: British Medical Journal</i> , 2002, 325, 860-860.	2.3	72
62	Columbia University's Informatics for Diabetes Education and Telemedicine (IDEATel) Project: Rationale and Design. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2002, 9, 49-62.	4.4	162
63	The Treatment of Hypertension in Adult Patients With Diabetes. <i>Diabetes Care</i> , 2002, 25, 134-147.	8.6	280
64	Nutrition Education Improves Metabolic Outcomes among Older Adults with Diabetes Mellitus: Results from a Randomized Controlled Trial. <i>Preventive Medicine</i> , 2002, 34, 252-259.	3.4	156
65	Thinking Outside the Box: Recent Advances in the Analysis and Presentation of Uncertainty in Cost-Effectiveness Studies. <i>Annual Review of Public Health</i> , 2002, 23, 377-401.	17.4	351
66	Task Force "the cost of prevention: can we afford it? Can we afford not to do it?". <i>Journal of the American College of Cardiology</i> , 2002, 40, 603-615.	2.8	21
68	Cost-Effectiveness Analysis of Stratified Versus Stepped Care Strategies for Acute Treatment of Migraine. <i>Pharmacoeconomics</i> , 2002, 20, 91-100.	3.3	52
69	Elevated blood pressure among U.S. adults with diabetes, 1988-1994   The full text of this article is available via AJPM Online at <a href="http://www.elsevier.com/locate/ajpmonline">http://www.elsevier.com/locate/ajpmonline</a> . <i>American Journal of Preventive Medicine</i> , 2002, 22, 42-48.	3.0	112
72	Treatment of Cardiovascular and Renal Risk Factors in the Diabetic Hypertensive. <i>Hypertension</i> , 2002, 40, 781-788.	2.7	95
73	The probability of cost-effectiveness. <i>BMC Medical Research Methodology</i> , 2002, 2, 5.	3.1	39
74	Diabetic care in Nigeria: report of a self-audit. <i>Journal of Diabetes and Its Complications</i> , 2002, 16, 159-164.	2.3	20
75	Comparing Cost-Effectiveness Analyses of Anti-Hypertensive Drug Therapy for Decision Making: Mission Impossible?. <i>Value in Health</i> , 2002, 5, 359-371.	0.3	10
76	Age structured models for diabetes in East Morocco. <i>Mathematics and Computers in Simulation</i> , 2002, 58, 215-229.	4.4	18

#	ARTICLE	IF	CITATIONS
77	Adherence to Antihypertensive Therapy With Fixed-Dose Amlodipine Besylate/Benazepril HCl Versus Comparable Component-Based Therapy. <i>Congestive Heart Failure</i> , 2003, 9, 324-332.	2.0	134
78	Variation in diabetes care by age: opportunities for customization of care. <i>BMC Family Practice</i> , 2003, 4, 16.	2.9	28
79	Health economics in the Hypertension Optimal Treatment (HOT) study: costs and cost-effectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension. <i>Journal of Internal Medicine</i> , 2003, 253, 472-480.	6.0	36
80	Facilitating best practice - cardiovascular risk management for patients with diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2003, 5, s29-s34.	4.4	1
81	Evidence-based treatment of hypertension in patients with diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2003, 5, 13-26.	4.4	15
82	The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). <i>Diabetic Medicine</i> , 2003, 20, 442-450.	2.3	223
83	A cost-utility analysis of tension-free vaginal tape versus colposuspension for primary urodynamic stress incontinence. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2003, 110, 255-262.	2.3	18
84	The benefits and costs of tamoxifen for breast cancer prevention. <i>Australian and New Zealand Journal of Public Health</i> , 2003, 27, 34-40.	1.8	22
85	Preventing cardiovascular disease in diabetes and glucose intolerance: evidence and implications for care. <i>Primary Care - Clinics in Office Practice</i> , 2003, 30, 569-592.	1.6	17
86	The Economic Impact of Hypertension. <i>Journal of Clinical Hypertension</i> , 2003, 5, 3-13.	2.0	86
87	Intensified multifactorial intervention and cardiovascular outcome in type 2 diabetes: the Steno-2 study. <i>Metabolism: Clinical and Experimental</i> , 2003, 52, 19-23.	3.4	65
89	Cost Effectiveness of Diabetes Mellitus Management Programs. <i>Disease Management and Health Outcomes</i> , 2003, 11, 439-453.	0.4	8
90	Use of cognitive therapy for relapse prevention in chronic depression. <i>British Journal of Psychiatry</i> , 2003, 182, 221-227.	2.8	104
91	Advantages of Using the Net-Benefit Approach for Analysing Uncertainty in Economic Evaluation Studies. <i>Pharmacoeconomics</i> , 2003, 21, 39-48.	3.3	91
92	The Economics of Screening and Treatment in Type 2 Diabetes Mellitus. <i>Pharmacoeconomics</i> , 2003, 21, 543-564.	3.3	28
93	Cognitive-behavioural therapy and motivational intervention for schizophrenia and substance misuse. <i>British Journal of Psychiatry</i> , 2003, 183, 418-426.	2.8	204
94	Improving Diabetes Processes of Care in Managed Care. <i>Diabetes Care</i> , 2003, 26, 2722-2727.	8.6	54
95	Specialist Nurse-Led Intervention to Treat and Control Hypertension and Hyperlipidemia in Diabetes (SPLINT): A randomized controlled trial. <i>Diabetes Care</i> , 2003, 26, 2250-2255.	8.6	154

#	ARTICLE	IF	CITATIONS
96	Management of Uncontrolled Hypertension in a Nurse-Led Clinic Compared With Conventional Care for Patients with Type 2 Diabetes. <i>Diabetes Care</i> , 2003, 26, 2256-2260.	8.6	134
97	Evaluation of methods for interval estimation of model outputs, with application to survival models. <i>Journal of Applied Statistics</i> , 2003, 30, 967-981.	1.3	2
98	Cost effectiveness analysis of neonatal extracorporeal membrane oxygenation based on four year results from the UK Collaborative ECMO Trial. <i>Archives of Disease in Childhood: Fetal and Neonatal Edition</i> , 2004, 89, F263-F268.	2.8	42
99	Diabetes Mellitus: Toward a Federal Policy. <i>Policy, Politics, and Nursing Practice</i> , 2004, 5, 237-242.	1.8	5
100	A Bayesian Approach to Net Health Benefits: An Illustration and Application to Modeling HIV Prevention. <i>Medical Decision Making</i> , 2004, 24, 634-653.	2.4	2
101	Intensive Integrated Therapy of Type 2 Diabetes: Implications for Long-Term Prognosis. <i>Diabetes</i> , 2004, 53, S39-S47.	0.6	91
102	The Vermont Diabetes Information System (VDIS): study design and subject recruitment for a cluster randomized trial of a decision support system in a regional sample of primary care practices. <i>Clinical Trials</i> , 2004, 1, 532-544.	1.6	54
103	Educational outreach in diabetes to encourage practice nurses to use primary care hypertension and hyperlipidaemia guidelines (EDEN): a randomized controlled trial. <i>Diabetic Medicine</i> , 2004, 21, 599-603.	2.3	34
104	Rational pharmacotherapy in the diabetic hypertension: analysis-prescribing patterns in a general hospital in Taiwan. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2004, 29, 547-558.	1.5	5
105	The lipid-regulating effects of atorvastatin on type 2 elder diabetes patients with hyperlipidemia. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2004, 24, 138-139.	1.0	0
106	A novel approach to treatment of hypertension in diabetic patients â€” a multicenter, double-blind, randomized study comparing the efficacy of combination therapy of Eprosartan versus Ramipril with low-dose Hydrochlorothiazide and Moxonidine on blood pressure levels in patients with hypertension and associated diabetes mellitus type 2 â€” rationale and design [ISRCTN55725285]. <i>Current Controlled Trials in Cardiovascular Medicine</i> , 2004, 5, 9.	1.5	6
107	Cost-effectiveness acceptability curvesâ€” facts, fallacies and frequently asked questions. <i>Health Economics (United Kingdom)</i> , 2004, 13, 405-415.	1.7	754
108	Cost-Effective Strategies in the Prevention of Diabetic Nephropathy. <i>Pharmacoeconomics</i> , 2004, 22, 9-28.	3.3	24
109	Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials. <i>Current Medical Research and Opinion</i> , 2004, 20, 1729-1746.	1.9	39
111	Are persons with diabetes practicing healthier behaviors in the year 2001? Results from the Behavioral Risk Factor Surveillance System. <i>Preventive Medicine</i> , 2004, 38, 203-208.	3.4	19
112	A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy. <i>Kidney International</i> , 2005, 68, 285-292.	5.2	63
113	Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK. <i>Diabetic Medicine</i> , 2005, 22, 1239-1245.	2.3	82
114	Assessing generalisability by location in trial-based cost-effectiveness analysis: the use of multilevel models. <i>Health Economics (United Kingdom)</i> , 2005, 14, 471-485.	1.7	92

#	ARTICLE	IF	CITATIONS
115	Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). <i>Diabetologia</i> , 2005, 48, 868-877.	6.3	147
117	The cost effectiveness of cardiovascular medicines. <i>Current Atherosclerosis Reports</i> , 2005, 7, 79-80.	4.8	4
118	Predictors of Health Care Costs in Adults With Diabetes. <i>Diabetes Care</i> , 2005, 28, 59-64.	8.6	193
119	Cost implications of new evidence on prevention of cardiovascular disease. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2005, 5, 183-192.	1.4	1
120	Specialist Nurse-Led Clinics to Improve Control of Hypertension and Hyperlipidemia in Diabetes: Economic analysis of the SPLINT trial. <i>Diabetes Care</i> , 2005, 28, 40-46.	8.6	59
121	Pro-Active Call Center Treatment Support (PACCTS) to Improve Glucose Control in Type 2 Diabetes: A randomized controlled trial. <i>Diabetes Care</i> , 2005, 28, 278-282.	8.6	93
122	Need for differential discounting of costs and health effects in cost effectiveness analyses. <i>BMJ: British Medical Journal</i> , 2005, 331, 446-448.	2.3	171
123	Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20536 individuals. <i>Lancet, The</i> , 2005, 365, 1779-1785.	13.7	106
124	Cost-effectiveness analysis of a kidney and cardiovascular disease treatment program in an Australian Aboriginal population. <i>Advances in Chronic Kidney Disease</i> , 2005, 12, 22-31.	1.4	24
125	Diabetes and hypertension, the deadly duet: importance, therapeutic strategy, and selection of drug therapy. <i>Cardiology Clinics</i> , 2005, 23, 139-152.	2.2	33
126	Cost-effectiveness of oral hypoglycaemic agents for the treatment of type 2 diabetes mellitus. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 601-608.	1.8	4
127	Cost Effectiveness of Preventive Interventions in Type 2 Diabetes Mellitus. <i>Pharmacoeconomics</i> , 2006, 24, 425-441.	3.3	42
129	The use of unequal randomisation ratios in clinical trials: A review. <i>Contemporary Clinical Trials</i> , 2006, 27, 1-12.	1.8	269
130	Optimising health care within given budgets: Primary prevention of cardiovascular disease in different regions of Sweden. <i>Health Policy</i> , 2006, 75, 214-229.	3.0	6
131	Management in general practice of hypertensive patients poorly controlled with a fixed-dose renin-angiotensin system inhibitor and diuretic combination: results from a French national survey. <i>Journal of Human Hypertension</i> , 2006, 20, 407-418.	2.2	2
132	A Randomized Trial Comparing Telemedicine Case Management with Usual Care in Older, Ethnically Diverse, Medically Underserved Patients with Diabetes Mellitus. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2006, 13, 40-51.	4.4	278
133	Predictors, consequences and costs of diabetes-related lower extremity amputation complicating type 2 diabetes: The Fremantle Diabetes Study. <i>Diabetologia</i> , 2006, 49, 2634-2641.	6.3	135
134	Clinic versus home blood pressure measurements in patients with CKD. <i>Current Diabetes Reports</i> , 2006, 6, 453-454.	4.2	0



#	ARTICLE	IF	CITATIONS
135	IMOP: randomised placebo controlled trial of outpatient cervical ripening with isosorbide mononitrate (IMN) prior to induction of labour – clinical trial with analyses of efficacy, cost effectiveness and acceptability. BMC Pregnancy and Childbirth, 2006, 6, 25.	2.4	15
136	Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation. BMC Health Services Research, 2006, 6, 52.	2.2	223
137	Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20%536 people. BMJ: British Medical Journal, 2006, 333, 1145.	2.3	80
138	Effect of nurse-directed hypertension treatment among First Nations people with existing hypertension and diabetes mellitus: the Diabetes Risk Evaluation and Microalbuminuria (DREAM 3) randomized controlled trial. Cmaj, 2006, 174, 1267-1271.	2.0	75
139	Review: PROactive O3: Pioglitazone, type 2 diabetes and reducing macrovascular events – economic implications?. British Journal of Diabetes and Vascular Disease, 2006, 6, 63-70.	0.6	7
140	Managing hypertension in patients with type 2 diabetes mellitus. American Journal of Health-System Pharmacy, 2006, 63, 1140-1149.	1.0	17
141	Is the Number of Documented Diabetes Process-of-Care Indicators Associated With Cardiometabolic Risk Factor Levels, Patient Satisfaction, or Self-Rated Quality of Diabetes Care?: The Translating Research into Action for Diabetes (TRIAD) study. Diabetes Care, 2006, 29, 2108-2113.	8.6	39
142	Limitations of Acceptability Curves for Presenting Uncertainty in Cost-Effectiveness Analysis. Medical Decision Making, 2007, 27, 101-111.	2.4	70
143	Glycemic Control and Absenteeism Among Individuals With Diabetes. Diabetes Care, 2007, 30, 1283-1285.	8.6	22
144	Understanding the Quality Chasm for Hypertension Control in Diabetes: A Structured Review of "Co-maneuvers" Used in Clinical Trials. Journal of the American Board of Family Medicine, 2007, 20, 469-478.	1.5	14
145	Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes. Current Medical Research and Opinion, 2007, 23, 609-622.	1.9	53
146	Improving management of chronic illness in the National Health Service: are better incentives really the key?. Chronic Illness, 2007, 3, 197-199.	1.5	0
147	Agreement Between Self-Reports and Medical Records Was Only Fair in a Cross-Sectional Study of Performance of Annual Eye Examinations Among Adults With Diabetes in Managed Care. Medical Care, 2007, 45, 876-883.	2.4	47
149	Long-Term Cost-utility Analysis of a Multidisciplinary Primary Care Diabetes Management Program in Ontario. Canadian Journal of Diabetes, 2007, 31, 205-214.	0.8	21
150	Studying the Hurdles of Insulin Prescription (SHIP©): development, scoring and initial validation of a new self-administered questionnaire. Health and Quality of Life Outcomes, 2007, 5, 53.	2.4	30
151	Pharmaco-economic issues for diabetes therapy. Best Practice and Research in Clinical Endocrinology and Metabolism, 2007, 21, 657-685.	4.7	26
152	Control of Blood Glucose and Insulin Resistance. , 2007, , 1105-1112.		1
153	Blood pressure control in type II diabetics with diabetic retinopathy. Eye, 2007, 21, 708-711.	2.1	15

#	ARTICLE	IF	CITATIONS
154	The cost-effectiveness of sibutramine in non-diabetic obese patients: evidence from four Western countries. <i>Obesity Reviews</i> , 2007, 8, 363-371.	6.5	15
155	PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK. <i>Diabetic Medicine</i> , 2007, 24, 982-1002.	2.3	26
156	The need for combination antihypertensive therapy to reach target blood pressures: what has been learned from clinical practice and morbidity-mortality trials?. <i>International Journal of Clinical Practice</i> , 2007, 61, 1592-1602.	1.7	25
157	Systemic Hypertension. <i>Current Problems in Cardiology</i> , 2007, 32, 201-259.	2.4	99
158	Health-Related Quality of Life and Cost-Effectiveness Components of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Rationale and Design. <i>American Journal of Cardiology</i> , 2007, 99, S90-S102.	1.6	24
159	Systemic Hypertension – Newer Guidelines. <i>Apollo Medicine</i> , 2007, 4, 189-196.	0.0	0
160	Taking the Pressure off Type 2 Diabetes Mellitus: Implementing Hypertension Guidelines. <i>Progress in Cardiovascular Nursing</i> , 2007, 22, 159-165.	0.4	1
161	Do economic evaluations have a role in decision-making in Medicine Management Committees? A qualitative study. <i>International Journal of Clinical Pharmacy</i> , 2007, 29, 661-670.	1.4	15
162	Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). <i>Cardiovascular Diabetology</i> , 2008, 7, 10.	6.8	38
163	Impact of the UKPDS – an overview. <i>Diabetic Medicine</i> , 2008, 25, 2-8.	2.3	30
164	The economic analyses of the UK prospective diabetes study. <i>Diabetic Medicine</i> , 2008, 25, 47-51.	2.3	11
165	Delivery of Multifactorial Interventions by Nurse and Dietitian Teams in a Community Setting to Prevent Diabetic Complications: A Quality-Improvement Report. <i>American Journal of Kidney Diseases</i> , 2008, 51, 425-434.	1.9	29
166	Cost-Effectiveness of Intensified Versus Conventional Multifactorial Intervention in Type 2 Diabetes. <i>Diabetes Care</i> , 2008, 31, 1510-1515.	8.6	130
167	Effect of Board Certification on Antihypertensive Treatment Intensification in Patients With Diabetes Mellitus. <i>Circulation</i> , 2008, 117, 623-628.	1.6	66
168	Explaining the Decline in Early Mortality in Men and Women With Type 2 Diabetes. <i>Diabetes Care</i> , 2008, 31, 1761-1766.	8.6	56
169	Benefits of hypertension management in diabetes: An opportunity not to be missed. <i>Blood Pressure</i> , 2008, 17, 248-249.	1.5	0
170	Diabetes risk evaluation and microalbuminuria (DREAM) studies: ten years of participatory research with a First Nation's home and community model for type 2 diabetes care in Northern Saskatchewan. <i>International Journal of Circumpolar Health</i> , 2008, 67, 190-202.	1.2	17
171	Statin Cost-Effectiveness in the United States for People at Different Vascular Risk Levels. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2009, 2, 65-72.	2.2	59

#	ARTICLE	IF	CITATIONS
172	Barriers to the self-care of type 2 diabetes from both patients' and providers' perspectives: literature review. <i>Journal of Nursing and Healthcare of Chronic Illness</i> , 2009, 1, 4-19.	0.5	33
173	An intensive nurse-led, multi-interventional clinic is more successful in achieving vascular risk reduction targets than standard diabetes care. <i>Irish Journal of Medical Science</i> , 2009, 178, 179-186.	1.5	14
174	An estimation of the long-term clinical and economic benefits of insulin lispro in Type 1 diabetes in the UK. <i>Diabetic Medicine</i> , 2009, 26, 803-814.	2.3	15
175	Long-Term Cost-Effectiveness of Pioglitazone versus Placebo in Addition to Existing Diabetes Treatment: A US Analysis Based on PROactive. <i>Value in Health</i> , 2009, 12, 1-9.	0.3	17
176	Estimation of mortality savings due to a national program for diabetes care. <i>European Journal of Internal Medicine</i> , 2009, 20, 307-312.	2.2	1
177	A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US. <i>Current Medical Research and Opinion</i> , 2009, 25, 1343-1353.	1.9	7
178	L'UKPDS 30 ans aprs: le livret de caisse d'pargne des diabologues. <i>Medecine Des Maladies Metaboliques</i> , 2009, 3, 137-140.	0.1	0
179	A Randomized Trial Comparing Telemedicine Case Management with Usual Care in Older, Ethnically Diverse, Medically Underserved Patients with Diabetes Mellitus: 5 Year Results of the IDEATel Study. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2009, 16, 446-456.	4.4	295
180	Pharmaco-economic issues for diabetes therapy. <i>Insulin</i> , 2009, 4, 32-60.	0.2	0
181	Appropriate, timely, and rational treatment of type 2 diabetes mellitus: Meeting the challenges of primary care. <i>Insulin</i> , 2009, 4, 144-157.	0.2	4
183	Cost-Effectiveness of Screening and Optimal Management for Diabetes, Hypertension, and Chronic Kidney Disease: A Modeled Analysis. <i>Value in Health</i> , 2010, 13, 196-208.	0.3	66
184	Caring for uninsured patients with diabetes: designing and evaluating a novel chronic care model for diabetes care. <i>Journal of Evaluation in Clinical Practice</i> , 2010, 16, 700-706.	1.8	6
185	Cost-effectiveness and socioeconomic implications of prevention and management of chronic kidney disease in type 2 diabetes. <i>Nephrology</i> , 2010, 15, S195-203.	1.6	8
186	Cost-effectiveness of lowering blood pressure with a fixed combination of perindopril and indapamide in type 2 diabetes mellitus: an ADVANCE trial-based analysis. <i>Medical Journal of Australia</i> , 2010, 193, 320-324.	1.7	12
187	Encounter Frequency and Blood Pressure in Hypertensive Patients With Diabetes Mellitus. <i>Hypertension</i> , 2010, 56, 68-74.	2.7	53
188	Cost-Effectiveness of Interventions to Prevent and Control Diabetes Mellitus: A Systematic Review. <i>Diabetes Care</i> , 2010, 33, 1872-1894.	8.6	383
190	Grado de control de la presi3n arterial en pacientes cr3nicos de Atenci3n Primaria. <i>Semergen</i> , 2010, 36, 554-561.	0.5	2
191	Economic evaluation alongside randomised controlled trials: design, conduct, analysis, and reporting. <i>BMJ: British Medical Journal</i> , 2011, 342, d1548-d1548.	2.3	232

#	ARTICLE	IF	CITATIONS
192	The cost-effectiveness of interventions in diabetes: A review of published economic evaluations in the UK setting, with an eye on the future. <i>Primary Care Diabetes</i> , 2011, 5, 9-17.	1.8	12
194	What should be the blood pressure target for diabetic patients?. <i>Current Opinion in Cardiology</i> , 2011, 26, 308-313.	1.8	9
195	Association of cardiac and non-cardiac chronic disease comorbidity on glycaemic control in a multi-ethnic population with type 1 and type 2 diabetes. <i>Postgraduate Medical Journal</i> , 2011, 87, 763-768.	1.8	13
196	Cost-effectiveness of a shared computerized decision support system for diabetes linked to electronic medical records. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2012, 19, 341-345.	4.4	27
197	Cost effectiveness of strategies to combat cardiovascular disease, diabetes, and tobacco use in sub-Saharan Africa and South East Asia: mathematical modelling study. <i>BMJ: British Medical Journal</i> , 2012, 344, e607-e607.	2.3	84
198	DPP-IV inhibitory potential of naringin: An in silico, in vitro and in vivo study. <i>Diabetes Research and Clinical Practice</i> , 2012, 97, 105-111.	2.8	81
199	Determinants of uncontrolled hypertension in adult type 2 diabetes mellitus: an analysis of the Malaysian diabetes registry 2009. <i>Cardiovascular Diabetology</i> , 2012, 11, 54.	6.8	35
200	Real-time continuous glucose monitoring (CGM) integrated into the treatment of type 1 diabetes: Consensus of experts from SFD, EVADIAC and SFE. <i>Diabetes and Metabolism</i> , 2012, 38, S67-S83.	2.9	36
201	Therapeutic Modalities in Diabetic Nephropathy: &lt;i>Future Approaches&/i>. <i>Open Journal of Nephrology</i> , 2012, 02, 5-18.	0.1	11
202	Therapeutic Modalities in Diabetic Nephropathy: Standard and Emerging Approaches. <i>Journal of General Internal Medicine</i> , 2012, 27, 458-468.	2.6	46
203	Impact of Specific Glucose-Control Strategies on Microvascular and Macrovascular Outcomes in 58,000 Adults With Type 2 Diabetes. <i>Diabetes Care</i> , 2013, 36, 3510-3516.	8.6	18
204	Management of hypertension in patients with type 2 diabetes mellitus. <i>South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care</i> , 2013, 55, 41-44.	0.6	0
205	The Role of Diet in the Prevention and Treatment of Diabetes. , 2013, , 615-628.		0
206	Do Older Adults Aged 60â€“75 Years Benefit From Diabetes Behavioral Interventions?. <i>Diabetes Care</i> , 2013, 36, 1501-1506.	8.6	35
207	The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index $\geq 30$ kg/m <sup>2</sup> in Spain. <i>Journal of Medical Economics</i> , 2013, 16, 926-938.	2.1	24
208	Body Mass Index: A Risk Factor for Retinopathy in Type 2 Diabetic Patients. <i>Mediators of Inflammation</i> , 2013, 2013, 1-8.	3.0	40
209	Barriers and Potential Solutions to Providing Optimal Guideline-Driven Care to Patients With Diabetes in the U.S.. <i>Diabetes Care</i> , 2013, 36, 3843-3849.	8.6	16
210	Gender of Physician as the Usual Source of Care and Patient Health Care Utilization and Mortality. <i>Journal of the American Board of Family Medicine</i> , 2013, 26, 138-148.	1.5	10

#	ARTICLE	IF	CITATIONS
211	Associated factors to self-rated health among hypertensive and/or diabetic elderly: results from Bambu- project. <i>Revista Brasileira De Epidemiologia</i> , 2013, 16, 559-571.	0.8	13
212	Hypertension in Diabetes Mellitus. , 2014, , 119-134.		0
213	Economic evaluation of the use of a pharmacogenetic diagnostic test in schizophrenia. <i>Health Policy and Technology</i> , 2014, 3, 314-324.	2.5	6
214	Differences in Health Services Utilization and Costs between Antihypertensive Medication Users Versus Nonusers in Adults with Diabetes and Concomitant Hypertension from Medical Expenditure Panel Survey Pooled Years 2006 to 2009. <i>Value in Health</i> , 2014, 17, 51-61.	0.3	5
215	Blood pressure control for diabetic retinopathy. <i>The Cochrane Library</i> , 2015, 1, CD006127.	2.8	91
216	Economic simulation of canagliflozin and sitagliptin treatment outcomes in patients with type 2 diabetes mellitus with inadequate glycemic control. <i>Journal of Medical Economics</i> , 2015, 18, 113-125.	2.1	6
217	Patient navigators for people with chronic disease: protocol for a systematic review and meta-analysis. <i>Systematic Reviews</i> , 2015, 4, 28.	5.3	22
218	Polypharmacy and specific comorbidities in university primary care settings. <i>European Journal of Internal Medicine</i> , 2016, 35, 35-42.	2.2	56
219	Response to: Important Considerations When Determining the Cost-effectiveness of Viscosupplements in the Treatment of Knee Osteoarthritis. <i>Advances in Therapy</i> , 2016, 33, 2273-2276.	2.9	3
221	Comparing metabolic control and complications in type 2 diabetes in two Pacific Islands at baseline and following diabetes care intervention. <i>Journal of Clinical and Translational Endocrinology</i> , 2016, 4, 32-37.	1.4	4
222	A study of an intelligent system to support decision making in the management of labour using the cardiotocograph - the INFANT study protocol. <i>BMC Pregnancy and Childbirth</i> , 2016, 16, 10.	2.4	24
223	Increasing trend of diabetes combined with hypertension or hypercholesterolemia: NHANES data analysis 1999-2012. <i>Scientific Reports</i> , 2016, 6, 36093.	3.3	36
224	Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP). <i>American Journal of Kidney Diseases</i> , 2016, 67, 576-584.	1.9	19
225	Time to Review the Role of Surrogate End Points in Health Policy: State of the Art and the Way Forward. <i>Value in Health</i> , 2017, 20, 487-495.	0.3	101
226	The Role of Diet in the Prevention and Treatment of Diabetes. , 2017, , 691-707.		0
227	Hypertension control after an initial cardiac event among Medicare patients with diabetes mellitus: A multidisciplinary group practice observational study. <i>Journal of Clinical Hypertension</i> , 2018, 20, 891-901.	2.0	2
228	Blood Pressure Management in Adults With Type 2 Diabetes: Insights From the Diabetes Mellitus Status in Canada (DM-SCAN) Survey. <i>Canadian Journal of Diabetes</i> , 2018, 42, 130-137.	0.8	25
229	Patient navigators for people with chronic disease: A systematic review. <i>PLoS ONE</i> , 2018, 13, e0191980.	2.5	177

#	ARTICLE	IF	CITATIONS
230	FIB-4 index is a marker for a subsequent decrease in insulin secretion in a non-diabetic Japanese population. <i>Scientific Reports</i> , 2020, 10, 15814.	3.3	1
231	Coping styles associated with glucose control in individuals with type 2 diabetes mellitus. <i>Journal of Diabetes Investigation</i> , 2020, 11, 1215-1221.	2.4	8
232	Cost-effectiveness of Interventions to Manage Diabetes: Has the Evidence Changed Since 2008?. <i>Diabetes Care</i> , 2020, 43, 1557-1592.	8.6	98
233	Cost-effectiveness of intensive interventions compared to standard care in individuals with type 2 diabetes: A systematic review and critical appraisal of decision-analytic models. <i>Diabetes Research and Clinical Practice</i> , 2020, 161, 108073.	2.8	3
234	Quality of Diabetes Care in Germany Improved from 2000 to 2007 to 2014, but Improvements Diminished since 2007. Evidence from the Population-Based KORA Studies. <i>PLoS ONE</i> , 2016, 11, e0164704.	2.5	46
235	The Effects of an 18-Month Walking Habit Intervention on Reducing the Medical Costs of Diabetes, Hypertension, and Hyperlipidemia—A Prospective Study. <i>Advanced Biomedical Engineering</i> , 2020, 9, 117-124.	0.6	4
236	Rationale and methodology for trial-based economic evaluation. <i>Clinical Investigation</i> , 2012, 2, 1191-1200.	0.0	6
237	Arterielle Hypertonie. , 2000, , 259-268.		0
238	Weitere kardiovaskuläre Risikofaktoren. , 2000, , 269-291.		0
239	Fettstoffwechsel, Übergewicht und Ernährung, <i>Diabetes</i> . , 2000, , 239-257.		0
240	The Diabetic Hypertensive (or Hypertensive Diabetic) - A Compelling Need to Optimize Blood Pressure. <i>Advances in Experimental Medicine and Biology</i> , 2001, 498, 119-125.	1.6	0
241	Management of type 2 diabetes. , 2002, , 1-24.		0
244	Time course of changes in carbohydrate and lipid metabolic parameters in patients with hypertensive disease during therapy with Rilmenidine versus Atenolol. <i>Arterial Hypertension (Russian Federation)</i> , 2004, 10, 28-32.	0.4	2
245	Screening for type 2 diabetes. , 2005, , 714-750.		0
246	Cost-Effectiveness of Full Medicare Coverage of Angiotensin-Converting Enzyme Inhibitors for Beneficiaries With Diabetes. <i>Yearbook of Cardiology</i> , 2006, 2006, 99-101.	0.0	0
247	Minimising polypharmacy in hypertension. <i>Independent Nurse</i> , 2009, 2009, .	0.1	0
248	Economic Costs of Diabetes and the Cost-Effectiveness of Interventions to Prevent and Control This Disease. , 2010, , 431-470.		0
250	UKPDS: A Faltering Success. <i>Endocrine Practice</i> , 1998, 4, 428-429.	2.1	0

#	ARTICLE	IF	CITATIONS
251	Treating type 2 diabetes. BMJ: British Medical Journal, 1999, 318, 666-666.	2.3	0
252	Hypertension and Diabetes. , 2022, , 263-291.		2
253	THE TREATMENT OF HYPERTENSION IN PATIENTS WITH DIABETES. Nursing Clinics of North America, 2001, 36, 273-289.	1.5	1
254	Two Distinct Groups Are Shown to Be at Risk of Diabetes by Means of a Cluster Analysis of Four Variables. Journal of Clinical Medicine, 2023, 12, 810.	2.4	0
255	Blood pressure control for diabetic retinopathy. The Cochrane Library, 2023, 2023, .	2.8	6
256	Measuring the Quality of Care of Diabetic Patients at the Specialist Outpatient Clinics in Public Hospitals in Singapore. Annals of the Academy of Medicine, Singapore, 2007, 36, 980-986.	0.4	8
257	The Economic Costs of Diabetes. , 2023, , 25-48.		0
258	Correlation between diabetic nephropathy and diabetic retinopathy as a long term complications of diabetes mellitus. Acta Marisensis - Seria Medica, 2023, 69, 176-181.	0.2	0
260	Cost-Effectiveness of Routine Monitoring of Long-Term Conditions in Primary Care: Informing Decision Modelling with a Systematic Review in Hypertension, Type 2 Diabetes and Chronic Kidney Disease. PharmacoEconomics - Open, 2024, 8, 359-371.	1.8	0